title: HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques.
abstract: Rhesus macaques were immunized with attenuated vaccinia or canarypox human immunodeficiency virus type 1 (HIV-1) recombinants and boosted with HIV-1 protein subunits formulated in alum. Following challenge with HIV-2SBL6669, three out of eight immunized macaques resisted infection for six months and another exhibited significantly delayed infection, whereas all three naive controls became infected. Immunizations elicited both humoral and cellular immune responses; however, no clear correlates of protection were discerned. Although more extensive studies are now called for, this first demonstration of cross-protection between HIV-1 and -2 suggests that viral variability may not be an insurmountable problem in the design of a global AIDS vaccine.
authors.affiliation: Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, USA.
authors.forename: A G
authors.initials: AG
authors.lastname: Abimiku
authors.forename: G
authors.initials: G
authors.lastname: Franchini
authors.forename: J
authors.initials: J
authors.lastname: Tartaglia
authors.forename: K
authors.initials: K
authors.lastname: Aldrich
authors.forename: M
authors.initials: M
authors.lastname: Myagkikh
authors.forename: P D
authors.initials: PD
authors.lastname: Markham
authors.forename: P
authors.initials: P
authors.lastname: Chong
authors.forename: M
authors.initials: M
authors.lastname: Klein
authors.forename: M P
authors.initials: MP
authors.lastname: Kieny
authors.forename: E
authors.initials: E
authors.lastname: Paoletti
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology; D000595:Amino Acid Sequence; D000818:Animals; D018150:Avipoxvirus; D004797:Enzyme-Linked Immunosorbent Assay; D015686:Gene Products, env / Q000737:chemistry / Q000276:immunology; D015483:HIV Antibodies / Q000032:analysis; D016655:HIV Core Protein p24 / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000276:immunology; D019302:HIV Envelope Protein gp160; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D015498:HIV-2 / Q000276:immunology*; D007117:Immunization, Secondary; D008253:Macaca mulatta; D008969:Molecular Sequence Data; D010446:Peptide Fragments; D010865:Pilot Projects; D011498:Protein Precursors / Q000737:chemistry / Q000276:immunology; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014616:Vaccinia virus
chemical_list: D016915:AIDS Vaccines; D015686:Gene Products, env; D015483:HIV Antibodies; D016655:HIV Core Protein p24; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; D010446:Peptide Fragments; D011498:Protein Precursors; D014614:Vaccines, Synthetic